Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB3 for delayed graft function after DCD kidney transplantation
NL-OMON39114Phase 2Active, not recruiting
- Sponsor
- Angion Biomedica Corp.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in delayed graft function (DGF) and acute kidney failure (AKF) comparing BB3 with Placebo (2 arms). Primary endpoint: Mean difference in creatinine clearance over time. Started Nov 2011; status: active, not recruiting.
02
Drugs
terevalefim
03
Conditions
delayed graft function (DGF)acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON39114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39114.